Delving into the Latest Updates on BioPoly LLC with Synapse

Overview

The goal of this randomized controlled clinical trial is to demonstrate the safety and effectiveness of the BioPoly® Partial Resurfacing Knee Implant for the treatment of cartilage defects of the distal femur in adult patients with knee pain and symptoms who are candidates for surgical intervention of the knee compared to outcomes for the control group.
The primary effectiveness endpoint is Month 24 composite clinical success (CCS) defined by:
* no secondary surgical intervention (SSI) and
* an improvement from baseline in the Knee injury and Osteoarthritis Outcome Score (KOOS) total score (scaled 0 to 100) of at least 10 points.
Researchers will compare the CCS for the investigational device group to a control group receiving the standard of care, either microfracture or debridement).
Subjects randomized to the investigational group will receive the BioPoly Knee device and those randomized to the control group will receive the current standard of care, either microfracture or debridement.

Start Date17 Mar 2025

Sponsor / Collaborator

BioPoly LLC

NCT02991300

/ CompletedNot Applicable

Open Label, Prospective, Consecutive Series Registry Database of BioPoly® RS Partial Resurfacing Patella Implant

The data registry will increase the knowledge of outcomes for treatment of focal cartilage defects of the patella treated with the BioPoly RS Patella Implant and will allow monitoring of the clinical safety and performance of the device and surgical implantation kit

Start Date01 Sep 2016

Sponsor / Collaborator

BioPoly LLC

NCT01473199

/ CompletedNot Applicable

Multi-centre, Open Label, Prospective, Consecutive Series Registry Database of BioPoly RS Partial Resurfacing Knee Implant

Information will be collected on the pre-op and post-op clinical status of patients with focal cartilage defects of the femoral condyles treated with the BioPoly RS Partial Resurfacing Knee Implant, a permanent orthopaedic implant. The overall aim of the study is to increase the knowledge of patient outcomes such as pain, knee function, level of activity, and overall quality of life after treatment with the device.

Start Date01 Nov 2011

Sponsor / Collaborator

BioPoly LLC

100 Clinical Results associated with BioPoly LLC

Login to view more data

0 Patents (Medical) associated with BioPoly LLC

Login to view more data

1

News (Medical) associated with BioPoly LLC

27 Jun 2009

·medcitynews.com

A tale of two researchers, MedCity Weekend Rounds June 26, 2009

An interesting juxtaposition this week in MedCity. First, there was the researcher who longs to do nothing but research. Then, by week’s end, we read of a program that hopes to do nothing but turn researchers into the next wave of biotech CEOs. There were other notable developments as well. Read them over and have a great weekend. Joblessness and uninsured go hand in hand, but some federal health-care proposals may stabilize the problems. Ganeden Biotech moved beyond humans with a probiotic for livestock feed. New products seems just around the corner in Minnesota and Indiana. CoAxia raised $21.5 million to complete trial of stroke device, and it looks like BioPoly is on track to commercialize its prosthetic technology. Ohio will get its first pluripotent stem cell facility — and advance a handful of commercialization projects — through a state grant and private match worth $10 million. Venture capital may be in a sad state, but there are still plenty of opportunities for health care.

100 Deals associated with BioPoly LLC

Login to view more data

100 Translational Medicine associated with BioPoly LLC

Login to view more data